Resilience amid transition: 11% growth masks margin miss and seasonal weakness

Revenue 356.7 Cr confirmed; YoY 11.2% confirmed; but NPM 16.0% delivered vs 17.6% claimed

Q1 EBITDA 15.7% correct; but historical pattern and macro uncertainty make 23–25% FY target ambitious

Management optimistic but implementation revenue down ~25% QoQ; contingent on project ramp; contingency risk

Consistent with stated ₹60 Cr quarterly; 40% YoY growth confirmed. Positive data point.

Virender Jeet stepping down; Tarun Nandwani (COO, 33 yrs tenure) assumes CEO effective Aug 1. Pramod appointed Chief Growth Officer. Execution risk.

Q1 implementation revenue declined ~₹12 Cr QoQ due to EMEA project start delays. Management expects recovery in Q2–Q3; contingency remains.

India revenue flat YoY at ₹96 Cr; base costs up 4–5%. Management initially guided 21% adj net margins; Q1 delivered 16%. India margin squeeze continues.

Management targets 23–25% full-year EBITDA (vs Q1 15.7%, implying significant recovery). Ambitious given FY26 prior miss and macro uncertainty.

SaaS/subscription revenue reached ₹60 Cr (+40% YoY), up from ₹43 Cr prior year. Now 17% of revenue; trajectory positive.

Tarun: Margin expansion from AI optimization in engineering practices; efficiency gains passed to customers for faster implementations. Management: Q1 is lowest margin quarter; full year typically 23–25% EBITDA.

Tarun: FY26 had lower license, but Q1 had good license bump. Impl revenue built from unexecuted order book + current quarter orders. Delays from customer environment, esp. India/EMEA. Expect Q2–Q3 recovery.

Tarun: Pipeline healthy in both. India: large NBFC/LOS/LMS/trade deals coming. EMEA: digital transformation, AI-led tools, SaaS. Mature markets subscription-based, continued growth.

Tarun: DSO is recognized challenge; showed decline Q4–Q1. Macro environment in EMEA caused some payment delays. Positive trend expected in coming quarters.

Tarun: AI demand strong across all RFPs. Newgen investing in vertical AI (CASA, lending, trade, ECM, etc.). Diversified across geographies/industries cushions macro headwinds.

Tarun: AI benefits as tailwind. Efficiencies in delivery timelines and operational performance broad-based across functions. Customer success remains core focus.

Deepti/Management: Bookings shared at end of year (March). Pipeline and booking numbers double-digit growth. RPO disclosure may come in future; currently booking growth better parameter.

Tarun: US mostly subscription-based; prior year wins accrue in coming quarters. Sitting on healthy base with new customer additions and mining. Deepti: 4 large deals disclosed; few in ₹12–16 Cr range, one ₹26 Cr.

Management: Seeing margin expansion. AI optimization driving productivity and growth. Will maintain ~20% margin on annual basis; not appropriate to comment beyond Q1.

Tarun: Delays from EMEA customer environmental factors. Projects have kicked off; expect Q2–Q3 recovery of ₹12 Cr shortfall and normal run rate.

Tarun: RFPs are fixed-price contracts; AI turnaround efficiencies passed to clients. Operational efficiencies accrue to Newgen on impl revenue. Support revenue split across large base; minimal demand pressure.

Management: No specific revenue guidance for company of this size. Hopeful for improved growth vs FY26. Targeting double-digit growth continuation.

Tarun: Deal count quarter-to-quarter varies; deal size grown substantially (₹15–16+ Cr deals). Middle East: UAE/Qatar/Kuwait mining deals strong. New deals from region. Africa/Europe also showing good pipeline.

Management: M&A under deliberation for years; finding right fit takes time. Dividend optimization ongoing. Buyback input given to Board; working on it.

Tarun: License mostly from India/EMEA. Mature markets mostly subscription. Delays in India/EMEA deal closures impact license. Pipeline healthy; recovery expected.

Tarun: Large India/EMEA deals: license + impl within 1 year. Impl recognized in 12–18 months. Others subscription (quarterly recognition).

Tarun: Strategy focused on customer success, innovation investment. Consistency and resilience in margins even with lower growth. No specific targets given.

Tarun: Evolved pricing for AI vertical offerings; remains work in progress. Trade, insurance, RMS, ECM pricing getting established. Will evolve as sales increase.

Tarun: Central banks publishing AI regulations. Customer ready to implement AI within compliance framework. This is sweet spot for Newgen. Seeing AI-based deal wins.

Management deferred; cited company size and macro uncertainty. Aspires to double-digit growth continuation vs FY26.

Implies significant recovery in Q2–Q4. Ambitious given prior miss (21% adjusted net margin not achieved). Contingent on implementation recovery and cost control.

Implementation revenue fell ~₹12 Cr QoQ due to EMEA project start delays. Management claims recovery in Q2–Q3, but project ramp contingent on customer execution. Risk of further delays into Q4.

India revenue ₹96 Cr flat YoY; base costs up 4–5%. Margin squeeze evident. No concrete plan to restore growth; recovery timing vague (later quarters).

Management targets 23–25% EBITDA full-year; Q1 delivered 15.7%. Implies Q2–Q4 avg ~26–28% EBITDA to hit midpoint. Aggressive given prior miss (21% adj net margin not achieved in FY26).

Virender Jeet (CEO) stepping down; Tarun Nandwani (COO, 33 yrs) assumes effective Aug 1. While Tarun is long-tenured, transition occurs amid weaker quarter and margin miss. No clarity on strategic direction shifts.

License revenue concentrated in India/EMEA; highly dependent on large deal closures. Delays in Q1 (project starts slow); recovery assumes Q2–Q4 closures materialize.

DSO management remains a challenge; macro environment in EMEA caused payment delays in Q1. Positive trend expected, but no specific timeline.